ANXA5 and head and neck neoplasm: It has already been confirmed that pre-treatment tumor-to-background ratios (T/N) of 99mTc-Annexin V activity can provide independent prognostic information on disease-free survival and overall survival in patients suffering from primary head and neck tumors [56].